Profile data is unavailable for this security.
About the company
Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company. The Company's technology, namely Fully Human Albumin Binding (FHAB), utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The Company designed the FHAB construct to improve drug accumulation in cancer tumors, as well as to extend the duration of activity in the body. Its lead asset, SON-1010, is a fully human single-chain version of Interleukin 12 (IL-12), covalently linked to the FHAB construct, for which it is pursuing clinical development in solid tumors. Its lead clinical-stage asset, SON-080, is a fully human version of IL-6 manufactured in Chinese Hamster Ovary (CHO) cells. SON-080, for its target indications of Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN). Its pipeline also includes SON-1210, SON-1410 and SON-3015.
- Revenue in USD (TTM)129.19k
- Net income in USD-14.46m
- Incorporated1999
- Employees12.00
- LocationSonnet Biotherapeutics Holdings Inc100 Overlook Center, Suite 102PRINCETON 08540United StatesUSA
- Phone+1 (609) 375-2227
- Fax+1 (302) 636-5454
- Websitehttps://www.sonnetbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Portage Biotech Inc | 0.00 | -144.90m | 5.14m | 7.00 | -- | 0.1607 | -- | -- | -7.96 | -7.96 | 0.00 | 1.62 | 0.00 | -- | -- | 0.00 | -111.60 | -19.70 | -113.27 | -26.48 | -- | -- | -- | -- | -- | -- | 0.0087 | -- | -- | -- | -520.10 | -- | -- | -- |
| Halberd Corp | 281.24k | 25.34k | 5.21m | 3.00 | 3.53 | -- | 205.53 | 18.54 | 0.0023 | 0.0023 | 0.0018 | -0.0002 | 0.1449 | 0.0303 | 2.52 | -- | 1.31 | -- | 4.58 | -- | 50.00 | -- | 9.01 | -- | 0.2661 | 1.35 | 1.02 | -- | 271.52 | -- | -60.11 | -- | -- | -- |
| Helix BioMedix, Inc. | 2.07m | -2.58m | 5.23m | 8.00 | -- | 3.35 | -- | 2.53 | -15.60 | -15.60 | 12.48 | 6.95 | 0.8047 | 1.87 | 4.55 | 258,238.80 | -100.64 | -146.31 | -120.73 | -173.57 | 68.96 | 30.80 | -125.06 | -527.12 | 1.69 | -14.57 | 0.00 | -- | 122.07 | 92.80 | 67.73 | -- | -29.08 | -- |
| Palisade Bio Inc | 250.00k | -12.30m | 5.26m | 9.00 | -- | 0.3377 | -- | 21.05 | -28.22 | -28.22 | 0.5485 | 18.30 | 0.0168 | -- | 0.3153 | 27,777.78 | -82.51 | -132.36 | -101.58 | -165.45 | -- | -- | -4,920.00 | -27,892.32 | -- | -856.33 | 0.0138 | -- | -- | -0.7814 | 13.74 | -- | 18.53 | -- |
| Cingulate Inc | 0.00 | -21.21m | 5.29m | 15.00 | -- | -- | -- | -- | -32.59 | -32.59 | 0.00 | -0.1109 | 0.00 | -- | -- | 0.00 | -199.61 | -- | -465.62 | -- | -- | -- | -- | -- | -- | -26.60 | 1.03 | -- | -- | -- | 14.65 | -- | -- | -- |
| Emmaus Life Sciences Inc | 28.46m | -4.74m | 5.36m | 55.00 | -- | -- | -- | 0.1885 | -0.0931 | -0.0931 | 0.3905 | -0.6773 | 0.6349 | 0.8184 | 9.36 | 517,454.50 | -10.58 | -- | -- | -- | 93.69 | -- | -16.66 | -- | 0.1249 | 0.1426 | -- | -- | -10.77 | -- | 33.37 | -- | -- | -- |
| Silo Pharma Inc | 72.12k | -3.63m | 5.37m | 3.00 | -- | 0.8893 | -- | 74.52 | -1.18 | -1.21 | 0.0234 | 2.13 | 0.0074 | -- | 2.19 | 24,040.00 | -37.46 | -24.90 | -39.95 | -26.39 | 91.90 | 82.79 | -5,034.79 | -2,757.85 | -- | -- | 0.00 | -- | 0.00 | -- | 7.07 | -- | -- | -- |
| First Wave BioPharma Inc | 0.00 | -16.10m | 5.43m | 15.00 | -- | 1.16 | -- | -- | -88.75 | -88.75 | 0.00 | 2.31 | 0.00 | -- | -- | 0.00 | -256.35 | -295.92 | -471.06 | -1,599.51 | -- | -- | -- | -- | -- | -790.91 | 0.1454 | -- | -- | -- | -7.55 | -- | -- | -- |
| Fresh Tracks Therapeutics Inc | 8.01m | -5.69m | 5.44m | 4.00 | -- | 0.5475 | -- | 0.6791 | -1.38 | -1.38 | 1.49 | 1.66 | 0.7326 | -- | -- | 2,001,500.00 | -52.10 | -89.76 | -66.50 | -115.24 | -- | -- | -71.12 | -442.61 | -- | -1,272.00 | 0.00 | -- | 15.31 | 37.62 | 73.02 | -- | -- | -- |
| Sonnet Biotherapeutics Holdings Inc | 129.19k | -14.46m | 5.46m | 12.00 | -- | 2.12 | -- | 42.29 | -12.91 | -12.91 | 0.0676 | 0.8381 | 0.0251 | -- | 0.1688 | 10,765.83 | -281.29 | -- | -- | -- | -- | -- | -11,192.09 | -- | -- | -- | 0.00 | -- | -57.76 | -- | 36.64 | -- | -- | -- |
| PaxMedica Inc | 0.00 | -18.29m | 5.53m | 6.00 | -- | 1.62 | -- | -- | -15.85 | -15.85 | 0.00 | 0.4574 | 0.00 | -- | -- | 0.00 | -463.93 | -755.77 | -915.89 | -- | -- | -- | -- | -- | -- | -1,760.66 | 0.00 | -- | -- | -- | -23.56 | -- | -- | -- |
| NLS Pharmaceutics AG | 0.00 | -15.47m | 5.60m | 2.00 | -- | -- | -- | -- | -0.534 | -0.534 | 0.00 | -0.1322 | 0.00 | -- | -- | 0.00 | -714.74 | -308.05 | -- | -- | -- | -- | -- | -- | -- | -175.42 | -- | -- | -- | -- | -38.08 | -- | -- | -- |
| Burzynski Research Institute Inc | 0.00 | -1.19m | 5.62m | 2.00 | -- | -- | -- | -- | -0.009 | -0.009 | 0.00 | -0.0003 | 0.00 | -- | -- | -- | -84,895.00 | -10,098.54 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 6.18 | -- | -- | -- |
| CeCors Inc | -100.00bn | -100.00bn | 5.78m | 6.00 | -- | -- | -- | -- | -- | -- | -- | -0.0163 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 22.70 | -- | -- | -- |
| Goldenwell Biotech Inc | 2.34k | -116.90k | 5.80m | -- | -- | 68.48 | -- | 2,479.23 | -0.0012 | -0.0012 | 0.00002 | 0.0009 | 0.0098 | 0.0071 | -- | -- | -49.07 | -- | -52.16 | -- | 47.01 | -- | -4,995.73 | -- | 37.75 | -- | 0.00 | -- | -95.10 | -- | 88.13 | -- | -- | -- |
Data as of Apr 30 2024. Currency figures normalised to Sonnet Biotherapeutics Holdings Inc's reporting currency: US Dollar USD
2.96%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Renaissance Technologies LLCas of 31 Dec 2023 | 43.75k | 1.43% |
| Citadel Securities LLCas of 31 Dec 2023 | 29.45k | 0.96% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 14.73k | 0.48% |
| Tower Research Capital LLCas of 31 Dec 2023 | 2.09k | 0.07% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 594.00 | 0.02% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2023 | 61.00 | 0.00% |
| Securities America Advisors, Inc.as of 31 Dec 2023 | 45.00 | 0.00% |
| Wells Fargo Bank, NA (Private Banking)as of 31 Dec 2023 | 21.00 | 0.00% |
| JPMorgan Asset Management (Europe) SARL (Germany)as of 31 Dec 2023 | 19.00 | 0.00% |
| Private Wealth Management Group LLC (New Jersey)as of 31 Dec 2023 | 3.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
